BCLI - ブレインスト―ム・セル・セラピュ―ティクス (Brainstorm Cell Therapeutics Inc.) ブレインスト―ム・セル・セラピュ―ティクス

 BCLIのチャート


 BCLIの企業情報

symbol BCLI
会社名 Brainstorm Cell Therapeutics Inc (ブレインスト―ム・セル・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS also known as Lou Gehrig's disease) Multiple Sclerosis (MS) and Parkinson's disease (PD) among others. Its subsidiary Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary) holds rights to commercialize the technology NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.   ブレインスト―ム・セル・セラピュ―ティクスは、米国のバイオテクノロジ―会社。筋萎縮性側索硬化症(ル―・ゲ―リック病としても知られている)、多発性硬化症、およびパ―キンソン病などの神経変性疾患を衰弱させるための成体幹細胞治療を開発する。「NurOwn」は、同社独自のプロセスで、神経変性疾患を治療するために設計されている。   Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
本社所在地 1325 Avenue of Americas 28th Floor New York NY 10019 USA
代表者氏名 Irit Arbel Irit Arbel
代表者役職名 Independent Chairman of the Board
電話番号 +1 201-488-0460
設立年月日 36770
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 24人
url www.brainstorm-cell.com
nasdaq_url https://www.nasdaq.com/symbol/bcli
adr_tso
EBITDA EBITDA(百万ドル) -7.44100
終値(lastsale) 3.62
時価総額(marketcap) 74823691.36
時価総額 時価総額(百万ドル) 75.44378
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 58.00478
当期純利益 当期純利益(百万ドル) -7.51600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Brainstorm Cell Therapeutics Inc revenues was not reported. Net loss increased 91% to $5.4M. Higher net loss reflects General and administrative - Balancing v increase of 93% to $2.6M (expense) Research and development - Balancing val increase of 85% to $2.4M (expense) Stock-based Compensation in SGA increase from $108K to $315K (expense).

 BCLIのテクニカル分析


 BCLIのニュース

   Brainstorm Announces Grant of a New Japanese Patent for NurOwn®  2020/09/16 11:30:00 PR Newswire
NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese Patent Office (JPO) has granted Brainstorm's Japanese Patent, number: 6,753,887,…
   BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn® Mechanism in ALS, Progressive MS and Alzheimer's Disease  2020/08/19 12:13:00 PR Newswire
NEW YORK, Aug. 19, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the publication of a manuscript titled, "Effects of MSC-NTF cells on T and B regulatory cell function…
   BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference  2020/08/10 11:30:00 PR Newswire
NEW YORK, Aug. 10, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview during…
   BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update  2020/08/05 11:00:00 PR Newswire
NEW YORK, Aug. 5, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the second quarter and first half ended June 30, 2020, and provided a corporate update….
   5 Stock Gainers for Thursday: Virgin Galactic, Cerence, Teladoc  2020/07/23 16:37:41 The Street
Brainstorm Cell Therapeutics, Virgin Galactic Holdings, Cerence, Teladoc Health, and Calix are some of Thursday's movers.
   Brainstorm Cell Therapeutics : KOL Presentation | MarketScreener  2020/07/08 11:06:24 MarketScreener
BrainstormCell Therapeutics July 8, 2020 KOL Webinar Phase 2 trial with NurOwn for Alzheimer's… | July 8, 2020
   BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program  2020/07/08 09:31:00 PR Newswire
NEW YORK, July 8, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader (KOL) webinar on its Alzheimer's Disease (AD) program today at 8:15 AM Eastern Time….
   BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS  2020/07/02 10:49:00 PR Newswire
NEW YORK, July 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that final participant dosing has been administered in the Phase 3 pivotal trial of NurOwn® (MSC-NTF…
   Brainstorm Cell Therapeutics : Presentation at the Raymond James Human Health Innovations Conference, 2020 | MarketScreener  2020/06/18 20:02:08 MarketScreener
Forward Looking Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve… | June 18, 2020
   The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study  2020/06/09 10:00:00 PR Newswire
WASHINGTON, June 9, 2020 /PRNewswire/ -- The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI), a biotechnology company, to support an amyotrophic lateral sclerosis (ALS) biomarker…
   Brainstorm Cell Therapeutics: Poor Cash And Specific Risks Make This An Avoid  2019/05/16 15:23:02 Seeking Alpha
   Pluristem Therapeutics - The Hidden Niche Player  2019/05/15 12:14:05 Seeking Alpha
   BrainStorm Cell Therapeutics misses by $0.13  2019/05/10 21:03:19 Seeking Alpha
   Brainstorm Cell Therapeutics (BCLI) Presents At BIO CEO & Investor Conference - Slideshow  2019/02/11 18:21:53 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ブレインスト―ム・セル・セラピュ―ティクス BCLI Brainstorm Cell Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)